Aprecitentan (Tryvio) efficacy and characteristics

Aprocitentan-Tryvio, as a new generation of endothelin receptor antagonist, has attracted much attention for its efficacy and characteristics in the treatment of hypertension. Compared with conventional calcium channel blockers, ACE inhibitors, ARB drugs or diuretics, aprecitentan exerts a vasodilatory effect by precisely blocking endothelin receptors. This mechanism is particularly important for patients with refractory hypertension. Clinically, some adult patients are still unable to achieve the ideal blood pressure target under combined treatment with traditional drugs, and long-term hypertension significantly increases the risk of cardiovascular events, including stroke and myocardial infarction. Through its unique mechanism of action, Aprecitentan can further reduce blood pressure and improve blood pressure control rate in combination therapy.

The drug has stable pharmacokinetics and can be taken orally once a day, greatly improving patient compliance. At the same time, aprecitentan has fewer interactions when used in combination with a variety of commonly used antihypertensive drugs, making clinical application more flexible. Its efficacy is not only reflected in the decrease in blood pressure, but also in reducing cardiovascular load by improving vascular compliance and reducing peripheral resistance, thereby indirectly reducing the risk of cardiovascular events. This has significant clinical value for the long-term management of patients with hypertension, especially those with multiple cardiovascular risk factors.

In terms of tolerability, aprecitentan shows good safety, with mild common adverse reactions and less fluctuations in liver function and hematological indicators, which means that patients are less likely to need to discontinue medication or dose adjustments during long-term use. Overseas practice shows that it has a stable auxiliary antihypertensive effect in combined therapy and can provide additional treatment space for patients with refractory hypertension. In the future, with the accumulation of more real-world data and guideline recommendations, aprecitentan is expected to become an important part of the standardized combination treatment of resistant hypertension, bringing patients a more optimized long-term blood pressure management strategy.

Reference materials:https://go.drugbank.com/drugs/DB15059